Right drug + Right dose + Right patient = Improved outcomes
Closing the loop between drug development and patient outcomes.
Biomimiks™ Platform
Empiriko’s proprietary Biomimiks™ in vitro technology closely mirrors the in vivo metabolism of liver enzymes (cytochrome P450), mimicking the structure and function of liver enzymes to predict metabolism patterns and profiles in humans.
Biomimiks™ platform includes a series of catalysts, biological processes and in silico modeling.
Biomimiks™ catalysts work in aqueous and non-aqueous experimental conditions – providing many advantages, including the systematic prediction, preparation, and identification of a spectrum of oxidative metabolites. These metabolites, even those that are highly reactive and unstable, have clinical relevance and may be active, inert, or toxic in different individuals and populations.
Empiriko’s current focus is to redesign existing antiviral drugs to increase efficacy, reduce toxicity and eliminate the need for coadministration of booster drugs (CYP3A inhibitors) which cause adverse reactions.
Personalized Metabolic Fingerprint™️ (PMF) Device
Empiriko’s Personalized Metabolic Fingerprint™️ (PMF) device provides physicians and patients a platform for assessment of drug-drug interactions, dose optimization, toxicity, early disease detection, and relevant clinical biomarkers in real-time. Using few drops of blood, this next generation point-of-care device provides three channels for assessment of drugs and clinically relevant biomarkers including:
Chemical Analysis
Miniaturized mass spectrometry measures blood levels and drug-drug interactions to optimize dosing.
Biomarker Analysis
Immunochemical biochip for early disease detection, and assessment of disease severity and progression.
Genetic Analysis
DNA/RNA biochip for genetic analysis for microbial infections and role of genetics in drug response.
Translational Analysis and Data Transmission
Empiriko’s analytic engine translates these data into actionable information which empowers physicians/patients to improve clinical outcomes. This information can be transmitted through the cloud to a clinician’s EMR and/or a patient’s smart phone within minutes from anywhere where an internet connection exists.
